Latest News for ASCLF
Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly SALD formulation compared to the U.S. Food and Drug Administration (FDA)-authorized tirzepatide once-weekly formulation.
HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sessions (taking place June 5-8, 2026, in New Orleans, Louisiana), highlighting its differentiated portfolio in obesity treatment, including small-molecule candidates, a peptide therapeutic, and an oral peptide…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ASCLF.
Senate Trading
No Senate trades found for ASCLF.
U.S. House Trading
No House trades found for ASCLF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.